Please login to the form below

Not currently logged in
Email:
Password:

Cushing disease

This page shows the latest Cushing disease news and features for those working in and with pharma, biotech and healthcare.

New data for Recordati’s Isturisa reinforces benefit in Cushing’s disease

New data for Recordati’s Isturisa reinforces benefit in Cushing’s disease

Recordati Rare Disease has revealed new data from a phase 3 trial of its Cushing’s disease treatment Isturisa. ... This data adds to the robust body of evidence supporting Isturisa as an effective and well-tolerated treatment for patients with

Latest news

  • FDA approves Recordati’s Cushing disease drug Isturisa FDA approves Recordati’s Cushing disease drug Isturisa

    Important new treatment option for patients with rare disorder. Italy’s Recordati has claimed FDA approval for Isturisa, an oral drug for adult Cushing’s disease patients who can’t be ... Cushing’s disease is a rare disorder that occurs when the

  • Novartis' acromegaly therapy cleared by FDA Novartis' acromegaly therapy cleared by FDA

    It leads to an increase in bone size, particularly those in the hands, feet and face, alongside other complications such as diabetes, arthritis, kidney disease and cancer. ... A short-acting formulation of Signifor that requires twice-daily dosing is

  • Novartis gets EU nod for rare disease drug Signifor Novartis gets EU nod for rare disease drug Signifor

    Signifor (pasireotide) was first approved in Europe in 2012 as a twice-daily subcutaneous injection for Cushing's disease, but the new depot formulation - called Signifor LAR - requires just one intramuscular ... It is also testing the new formulation

  • Novartis plans filings for acromegaly candidate Novartis plans filings for acromegaly candidate

    A twice-daily formulation of Signifor (pasireotide) is already on the market for the treatment of Cushing's disease, but the latest study assessed a once-monthly intramuscular formulation - called Signifor ... The company has already filed for approval

  • Novartis cancer chief Hoppenot leaves for top job at Incyte Novartis cancer chief Hoppenot leaves for top job at Incyte

    During his time at the helm of Novartis' cancer division Hoppenot presided over the launch of two new cancer therapies, Jakavi for myelofibrosis in 2011 and Signifor (pasireotide) for Cushing's ... disease in 2012, while rolling out new indications for

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics